Melichar B, Voboril Z, Cerman J Jr, Melicharova K, Mergancova J, Voboril R, Jandik P. Survival of patients with colorectal cancer liver metastases treated by regional chemotherapy.
Hepatogastroenterology. 2006 May-Jun;53(69):426-34.

Assenat E, Duffour J, Ychou M.  [Irinotecan for the treatment of metastatic colorectal cancer] Bull Cancer. 2006 May 1;93(5):507-15. Review. French.

Zheng H, Chen JZ, Liao WJ, Luo RC.  [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]
Nan Fang Yi Ke Da Xue Xue Bao. 2006 May;26(5):689-91. Chinese.

Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, McMillan DC. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006 Jun 19;94(12):1833-6.

Hu JB, Sun XN, Yang QC, Xu J, Wang Q, He C. Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer. World J Gastroenterol. 2006 Apr 28;12(16):2610-4.

Sturm I, Rau B, Schlag PM, Wust P, Hildebrandt B, Riess H, Hauptmann S, Dorken B, Daniel PT. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.
BMC Cancer. 2006 May 10;6(1):124

Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL.  Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.
J Clin Oncol. 2006 May 20;24(15):2368-75.

Hasegawa S, Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tajima T, Nakasaki H, Makuuchi H. Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination. Oncol Rep. 2006 May;15(5):1185-90.

Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, Gonzalez-Baron M. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006 Apr 10;94(7):969-75.

Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006 Mar 27;94(6):798-805.

Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
J Clin Oncol. 2006 Mar 20;24(9):1395-403.

Ortholan C, Francois E, Thomas O, Benchimol D, Baulieux J, Bosset JF, Gerard JP. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials.
Dis Colon Rectum. 2006 Mar;49(3):302-10.